20 Week Bridging Study in Type II DM

A Multicenter, Non-Comparative, Open, Phase III Study to Evaluate the Efficacy and Safety of Insulin Glargine on Subjects With Type 2 Diabetes Mellitus

A multicenter, non-comparative, one arm, open, phase III study to evaluate the efficacy and safety of insulin glargine on subjects with Type 2 Diabetes Mellitus

Inclusion Criteria:

• Type 2 Diabetes Mellitus diagnosed at least 3 years ago
• Treated concomitantly with insulin once a day and SU over at least 3 months prior to study entry
• Treated with OHA monotherapy over at least 1 year
• HbA1c greater than or equal to 7.5% and less than or equal to 12.0%, at visit 1 (screening visit)
• BMI < 40 kg/m2
• No history of ketonemia
• Women of childbearing potential using the medically approved contraceptive method
• Ability and willingness to perform blood glucose monitoring using a blood glucose meter as per the requirement of protocol

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.